Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043889 | 0.91 | HRH3 (0.40) | HRH3KCNH2CYP2D6SLC6A4ALDH1A1 | |
| SCHEMBL13043912 | 0.87 | HRH3 (0.42) | HRH3KCNH2CYP2D6SLC6A4ALDH1A1 | |
| SCHEMBL13043886 | 0.83 | L3MBTL1 (0.42) | HRH3KCNH2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL13043882 | 0.81 | HRH3 (0.39) | HRH3KCNH2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL13043895 | 0.80 | L3MBTL1 (0.40) | HRH3KCNH2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL13043896 | 0.80 | HRH3 (0.34) | HRH3KCNH2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL13043907 | 0.79 | HRH3 (0.48) | HRH3KCNH2CYP2D6SLC6A4ALDH1A1 | |
| SCHEMBL13043893 | 0.79 | HRH3 (0.37) | HRH3KCNH2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL13043918 | 0.78 | PAOX (0.44) | HRH3KCNH2CYP2D6SLC6A4ALDH1A1 | |
| SCHEMBL13043935 | 0.76 | HRH3 (0.46) | HRH3KCNH2CYP2D6SLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | HRH3 1002/4885KCNH2 200/4885CYP2D6 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.